Known as GPS for the Body, the Calypso System utilizes transponders to setup and continuously track the position of targeted tissue during radiation treatment. In the event that the tumor site moves outside of acceptable limits, the clinician adapts therapy during daily treatment to ensure the treatment is delivered as prescribed to the cancerous tissue while avoiding adjacent healthy organs. This is said to be the only technology platform designed to provide objective, accurate and continuous tracking information during external beam radiation therapy without adding ionizing radiation.
Eric Meier, CEO and President of Calypso, said: “Extending the clinical use of the Calypso System is vital for post-prostatectomy patients at risk or diagnosed with recurrent prostate cancer. Clinicians gain increased confidence when treating these patients. This new indication broadens the spectrum of prostate cancer patients who will benefit from continuous target tracking during radiation therapy.”